IONIC Trial Abstract Published at ASCO

Noxopharm Limited. ABN 50 608 966 123 Level 20, Tower A, The Zenith, 821 Pacific Highway, Chatswood NSW 2067 AUSTRALIA IONIC Trial Abstract Published at ASCO • Preliminary data from IONIC study by principal investigator • Annual meeting of the American Society of Clinical Oncology (ASCO) • Investigator-initiated trial across six Australian sites Sydney, 26 May 2023: Innovative biotech company Noxopharm Limited (ASX:NOX) announces preliminary data from the IONIC investigator-initiated pilot Phase 1 trial of oncology drug candidate Veyonda® has been published online in the form of an abstract at the American Society of Clinical Oncology (ASCO) annual meeting taking place in Chicago from 2-6 June 2023. ASCO is the world's leading professional organisation for physicians and oncology professionals caring for people with cancer, and its annual meeting is the world’s largest gathering of oncology physicians, industry representatives, researchers, patient advocates and investment analysts. IONIC is exploring the potential of Veyonda to increase the activity of Bristol Myers Squibb's Opdivo® (nivolumab) immune checkpoint inhibitor in different types of cancer. The trial is being led by principal investigator Professor Paul de Souza, a consultant medical oncologist, a Professor of Medicine at the University of Sydney based at the Nepean Cancer Centre, a conjoint Professor in the Faculty of Medicine, UNSW Australia, and a former Foundation Professor of Medical Oncology at Western Sydney University. He has research agreements with Bristol Myers Squibb and Noxopharm to conduct the IONIC trial, administering both Veyonda and Opdivo in up to 30 patients across six sites in the Sydney area and regional NSW. Abstract title: A Phase I/II trial of NOX66 in combination with nivolumab in patients (pts) with advanced cancer Link: https://meetings.asco.org/abstracts-presentations/224651 -ENDS- About IONIC IONIC is an investigator-initiated pilot-study exploring the safety and efficacy signals of Veyonda in combination with Bristol Myers Squibb’s immune checkpoint inhibitor (ICI) Opdivo® (nivolumab) for patients with solid tumours. ICIs such as nivolumab have had impressive results in some cancer types. However, primary and secondary resistance to checkpoint blockage remains a clinical challenge. The aim of the study is to increase the activity of nivolumab by using Veyonda to overcome tumour resistance to ICI therapy. Noxopharm Limited. ABN 50 608 966 123 Level 20, Tower A, The Zenith, 821 Pacific Highway, Chatswood NSW 2067 AUSTRALIA There are two cohorts: one cohort of patients that has progressed on ICIs and one cohort with patients who are treatment-naïve to ICIs. Both cohorts are enrolled in parallel. Approximately 30 patients at a number of Australian sites are being invited to participate in the study. The study involves an initial dose escalation phase, followed by dose expansion. About Noxopharm Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines. The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement). Noxopharm also has a major shareholding in US biotech company Nyrada Inc (ASX:NYR), which focuses on drug development for cardiovascular and neurological diseases. To learn more, please visit: noxopharm.com Investor, Corporate & Media enquiries: Julian Elliott M: 0425 840 071 E: [email protected] Company Secretary: David Franks T: +61 2 8072 1400 E: [email protected] Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors. Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward- looking statement.

The release as fetched from its publisher. noxopharm.com ↗